M Bourliere

Summary

Affiliation: Saint Joseph Hospital
Country: France

Publications

  1. ncbi [New perspective in chronic hepatitis B therapy]
    M Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, 26, bd de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 32:S64-9. 2008
  2. ncbi Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients
    P Halfon
    Laboratoire Alphabio, Marseille, France
    Aliment Pharmacol Ther 30:61-70. 2009
  3. ncbi Analogs and fibrosis regression in hepatitis B
    M Bourliere
    Department of Hepato Gastroenterology, Hopital Saint Joseph, 26, boulevard de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 33:923-9. 2009
  4. ncbi How to optimize HCV therapy in genotype 1 patients with cirrhosis
    Marc Bourliere
    Department of Hepato Gastroenterology, Hospital Saint Joseph, Marseille, France
    Liver Int 33:46-55. 2013
  5. ncbi Future treatment of patients with HCV cirrhosis
    Marc Bourliere
    Department of Hepato Gastroenterology, Hospital Saint Joseph, Marseille, France
    Liver Int 32:113-9. 2012
  6. ncbi Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
  7. ncbi [Severe hepatopathies in HIV patients. Epidemiology and diagnosis]
    M Bourliere
    Service d Hepato gastro enterologie, Hopital Saint Joseph, 26, boulevard de Louvain, 13008 Marseille, France
    Med Mal Infect 34:1-3. 2004
  8. ncbi [Transmission of hepatitis B and C viruses from caregiver to patients: myths and reality]
    Marc Bourliere
    Service d Hepatogastroenterologie, Fondation Hopital Saint Joseph, 26, bd de Louvain, 13008 Marseille
    Gastroenterol Clin Biol 27:291-3. 2003
  9. ncbi [Treatment of hepatitis C: therapeutic management]
    M Bourliere
    , , 26, boulevard de Louvain, 13255 Marseille cedex 08, France
    Gastroenterol Clin Biol 32:S166-71. 2008
  10. ncbi [Treatment of hepatitis C]
    Marc Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, 13008 Marseille, France
    Rev Prat 61:55-60. 2011

Detail Information

Publications34

  1. ncbi [New perspective in chronic hepatitis B therapy]
    M Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, 26, bd de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 32:S64-9. 2008
    ..However additional larger scale and more systematic studies of the understanding of HBV specific T-cell response have to be performed in order to select which patient can benefit of such therapies...
  2. ncbi Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients
    P Halfon
    Laboratoire Alphabio, Marseille, France
    Aliment Pharmacol Ther 30:61-70. 2009
    ..Few data have reported the influence of IR on steatosis and fibrosis in the context of HIV-HCV coinfection...
  3. ncbi Analogs and fibrosis regression in hepatitis B
    M Bourliere
    Department of Hepato Gastroenterology, Hopital Saint Joseph, 26, boulevard de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 33:923-9. 2009
    ....
  4. ncbi How to optimize HCV therapy in genotype 1 patients with cirrhosis
    Marc Bourliere
    Department of Hepato Gastroenterology, Hospital Saint Joseph, Marseille, France
    Liver Int 33:46-55. 2013
    ..Ultimately, an interferon-free regimen of DAAs combinations will probably provide a SVR in patients with cirrhosis and will probably be proposed in patients with more advanced or decompensated cirrhosis...
  5. ncbi Future treatment of patients with HCV cirrhosis
    Marc Bourliere
    Department of Hepato Gastroenterology, Hospital Saint Joseph, Marseille, France
    Liver Int 32:113-9. 2012
    ..First generation protease inhibitors plus PR appear to be a new step forward in the management of HCV genotype 1 patients with cirrhosis...
  6. ncbi Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  7. ncbi [Severe hepatopathies in HIV patients. Epidemiology and diagnosis]
    M Bourliere
    Service d Hepato gastro enterologie, Hopital Saint Joseph, 26, boulevard de Louvain, 13008 Marseille, France
    Med Mal Infect 34:1-3. 2004
  8. ncbi [Transmission of hepatitis B and C viruses from caregiver to patients: myths and reality]
    Marc Bourliere
    Service d Hepatogastroenterologie, Fondation Hopital Saint Joseph, 26, bd de Louvain, 13008 Marseille
    Gastroenterol Clin Biol 27:291-3. 2003
  9. ncbi [Treatment of hepatitis C: therapeutic management]
    M Bourliere
    , , 26, boulevard de Louvain, 13255 Marseille cedex 08, France
    Gastroenterol Clin Biol 32:S166-71. 2008
  10. ncbi [Treatment of hepatitis C]
    Marc Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, 13008 Marseille, France
    Rev Prat 61:55-60. 2011
    ..New direct antiviral agents will become soon available and will lead to an improvement of sustained virological response with maybe more complex therapy leading to a new management of patients...
  11. ncbi Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007)
    Marc Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, Marseille, France
    Antivir Ther 17:101-10. 2012
    ..The aim of this study was to document in real life the characteristics and management of hepatitis C patients treated with pegylated interferon-α2a and ribavirin, and the efficacy of treatment (sustained virological response [SVR])...
  12. ncbi Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users
    M Bourliere
    Department of Gastroenterology and Liver Unit, Hopital Saint Joseph, France
    J Viral Hepat 9:62-70. 2002
    ....
  13. ncbi Combining non-invasive methods for assessment of liver fibrosis
    M Bourliere
    Department of Hepato gastroenterology Hôpital Saint Joseph, 26 Boulevard de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 32:73-9. 2008
    ..They may also be useful in clinical practice and particularly for large-scale screening of HCV patients...
  14. ncbi Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients
    M Bourliere
    Département d Hépato Gastroentérologie, Hopital Saint Joseph, Marseille, France
    Aliment Pharmacol Ther 28:458-67. 2008
    ..Non-invasive liver fibrosis scores such as Hepascore (HS) have been proposed as an alternative to liver biopsy in hepatitis C virus (HCV)-infected patients...
  15. ncbi Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
    D Roulot
    Service d Hepatogastroenterologie, Hopital Jean Verdier, Bondy, France
    J Viral Hepat 14:460-7. 2007
    ..In conclusion, the distribution of HCV-4 subtypes varies with the geographical origin of transmission and affects the SVR following antiviral treatment...
  16. ncbi Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor
    P Halfon
    Alphabio Laboratory, Department of Biochemistry, Hopital de la Conception, Marseille, France
    J Clin Microbiol 36:2073-5. 1998
    ..9- to 5.6-fold with Monitor. These large spontaneous fluctuations (up to 0.75 log), observed daily, weekly, and monthly, raise doubt about the clinical value of a single assessment of pretherapeutic viremia...
  17. ncbi Slow viral dynamics of hepatitis C virus genotype 4
    P Halfon
    Alphabio Laboratory, Virological Department, Marseille, France
    J Viral Hepat 10:351-3. 2003
    ..The viral dynamics parameters of HCV-4 appear similar to those of HCV-1 and slower than those of HCV-2. HCV-4 infected patients should be grouped with those with HCV-1 when therapeutic schemes are considered in relation to genotype...
  18. ncbi Covert transmission of hepatitis C virus during bloody fisticuffs
    M Bourliere
    Department of Hepatogastroenterology, Hopital Saint Joseph, Marseille, France
    Gastroenterology 119:507-11. 2000
    ..This example of transmission could have a major impact in sports such as boxing or rugby. We suggest that in any fight, single use or nondisposable material should be used to dry blood to avoid such contamination...
  19. ncbi Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
    P Halfon
    Alphabio Laboratory, Marseille, France
    J Viral Hepat 13:329-35. 2006
    ..Genotype A was associated with HBeAg positivity and genotype D with HBe antibody positivity. In our European patients, we find no clear association between a given HBV genotype and liver disease severity...
  20. ncbi Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies
    M Bourliere
    Department of Hepato-Gastroenterology, Saint-Joseph Hospital, Marseille, France
    J Viral Hepat 13:659-70. 2006
    ..The combination of all tests without liver biopsy allowed 191/235 (81.3%) patients to be correctly classified; liver biopsy remained mandatory in some patients (18.7%)...
  21. ncbi Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy)
    Philippe Halfon
    Alphabio Laboratory, Ambroise Pare Hospital, Marseille, France
    J Med Virol 82:2027-31. 2010
    ..Among non-selected consecutive non-responder patients, re-treatment with PEG IFN-α-2a + RIBA is associated with virological response regardless of the presence of antibody-mediated resistance to conventional IFN treatment...
  22. ncbi Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene)
    P Halfon
    Departement de Virologie, Laboratoire Alphabio, 23 Rue de Friedland, Hopital Ambroise Pare, 13006, Marseille, France
    J Clin Microbiol 39:1771-3. 2001
    ..The Trugene and InnoLiPA assays gave concordant results within HCV types in 100% of cases. The ability to discriminate at the subtype level was 76 and 74% for the Trugene and the InnoLiPA assays, respectively...
  23. ncbi [Analogs combination therapy in chronic hepatitis B: when and how?]
    A Kahloun
    Service d Hépato gastroentérologie Hôpital Saint Joseph, Marseille, France
    Gastroenterol Clin Biol 34:S126-35. 2010
    ....
  24. ncbi Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
    C Bonny
    Service d Hepato Gastroenterologie, Hotel Dieu, Clermont Ferrand, France
    Aliment Pharmacol Ther 24:593-600. 2006
    ..To assess the rate of sustained virological response in naïve hepatitis C virus-type 5 patients treated by standard interferon or pegylated-interferon [corrected] (peg-interferon) and ribavirin combination for 48 weeks...
  25. ncbi Optimization and robustness of blood tests for liver fibrosis and cirrhosis
    Paul Cales
    Service d Hepato Gastroenterologie, CHU, Angers, France
    Clin Biochem 43:1315-22. 2010
    ..To optimize the performance and feasibility of fibrosis blood tests and evaluate their robustness...
  26. ncbi [Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease]
    Marc Bourliere
    Service d Hepatogastroenterologie, Hopital Saint Joseph, 26 Boulevard de Louvain, Marseille
    Gastroenterol Clin Biol 31:895-905. 2007
  27. ncbi Chlormezanone-induced fulminant hepatitis in a pregnant woman: successful delivery and liver transplantation
    M Bourliere
    Service d Hepatologie, Hopital de la Conception, Marseille, France
    J Gastroenterol Hepatol 7:339-41. 1992
    ..The mother and her baby were in good condition 26 months after liver transplantation. In this case, chlormezanone was probably responsible for the fulminant hepatitis...
  28. ncbi Serological response to infection with different isolates of hepatitis C virus
    P Halfon
    Alphabio Laboratory, Hopital Ambroise Pare, Marseille, France
    J Viral Hepat 9:438-42. 2002
    ..These results demonstrate that using a single test is adequate in the routine diagnosis of HCV infection in clinical laboratory, as recommended by the last French and European consensus conference...
  29. ncbi [Clinical practice guidelines on the use of liver biopsy]
    Jean-Baptiste Nousbaum
    , CHU La Cavale Blanche, Brest, France
    Gastroenterol Clin Biol 26:848-78. 2002
  30. ncbi [Sarcoidosis following pegylated interferon therapy: two cases]
    Souad Benali
    , , Marseille
    Gastroenterol Clin Biol 30:615-9. 2006
    ..The second patient developed cutaneous lesions after 6 months of treatment. Resolution occurred after the discontinuation of the treatment. In these two cases ribavirin was stopped before the first signs of sarcoidosis...
  31. ncbi [Inactive carrier of hepatitis B virus]
    Marc Bourliere
    Hépato Gastroentérologie, Hopital Saint Joseph, Marseille, France
    Gastroenterol Clin Biol 29:369-73. 2005
  32. ncbi Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone
    Victor de Ledinghen
    Service d Hepato Gastroenterologie, Centre Hospitalier Universitaire, Hopital du Haut leveque, 33604 Pessac Cedex, France
    J Hepatol 36:819-26. 2002
    ....
  33. ncbi Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C
    Victor de Ledinghen
    Service d Hepato Gastroenterologie, Centre Hospitalier Universitaire, Pessac, France
    J Hepatol 36:672-80. 2002
    ..We compared the efficacy and safety of daily interferon alfa-2b in combination with ribavirin with those of interferon alfa-2b three times a week alone or in combination with ribavirin...
  34. ncbi [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]
    Marc Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, 26 bd de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 30:3S34-6. 2006